Cosmo Achieves Robust Financial Performance in H1 2024 and Confirms Its Full Year Guidance @Cosmo_Pharma #HealthCare #OTC #OTCMarkets #OTCStocks #Investing
Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - July 24, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its 2024 half year results. Key highlights Health Tech: Upfront payment of $100 million received from Medtronic related to expansion of AI-driven partnership; Cosmo expects to receive an additional $100m from Medtronic this year linked to new services and the delivery of...
http://dlvr.it/TB0D1r
http://dlvr.it/TB0D1r
Comments
Post a Comment